2 results
Approved WMORecruiting
The primary objective of the study is to determine the efficacy of AP26113, as evidenced by objective response rate, in patients with ALK positive locally advanced or metastatic NSCLC whose disease has progressed on therapy with crizotinib.
Approved WMORecruiting
The study is divided in two phases.The primary objective of phase I of the study is to evaluate the safety and toxicity of the infusion of ex vivo expanded UCB-NK cells, both with and without sc IL-2 following immunosuppressive conditioning therapy…